SCHEMBL25848113

SCHEMBL25848113

Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1NC(N)=S

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BTK Q06187 1/20 0.60
KIT P10721 9/20 0.57
ABL1 P00519 8/20 0.57
BCR P11274 4/20 0.57
LCK P06239 6/20 0.56
CSF1R P07333 6/20 0.56
ABL2 P42684 5/20 0.56
BRAF P15056 4/20 0.56
EGFR P00533 3/20 0.56
PDGFRA P16234 3/20 0.56
MAPK14 Q16539 3/20 0.56
ERBB2 P04626 2/20 0.56
FYN P06241 2/20 0.56
LYN P07948 2/20 0.56
PDGFRB P09619 2/20 0.56
FGR P09769 2/20 0.56
SRC P12931 2/20 0.56
NQO2 P16083 2/20 0.56
EPHA8 P29322 2/20 0.56
FRK P42685 2/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL724511 0.90 BTK (0.60) BTKKITABL1BCRLCK
SCHEMBL31436906 0.89 BTK (0.62) BTKKITABL1BCRLCK
SCHEMBL8214408 0.85 BTK (0.59) BTKKITABL1BCRLCK
SCHEMBL15381992 0.85 BTK (0.69) BTKKITABL1BCRLCK
SCHEMBL4006161 0.84 BTK (0.63) BTKKITABL1BCRLCK
SCHEMBL846560 0.84 BTK (0.65) BTKKITABL1BCRLCK
SCHEMBL31436860 0.84 BTK (0.65) BTKKITABL1BCRLCK
SCHEMBL3557025 0.83 BRAF (0.74) KITCSF1RBRAFEGFR
SCHEMBL19646438 0.83 BTK (0.57) BTKKITABL1BCRLCK
SCHEMBL3709638 0.82 BTK (0.63) BTKKITABL1BCRLCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250092032-A1 DEOXYCYTIDINE KINASE INHIBITORS INSTITUT JEAN PAOLI & IRENE CALMETTES CENTRE REGIONAL DE LUTTE CONTRE LE CANCER (FR) 2025-03-20 US disclosed
WO-2023135330-A1 DEOXYCYTIDINE KINASE INHIBITORS CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2023-07-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250092032-A1 DEOXYCYTIDINE KINASE INHIBITORS DCK, DTYMK, TYMP BTK 559/4885KIT 509/4885ABL1 147/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.